Stevanato Group S.p.A. (STVN) stock
Close on Nov 16, 2026Market cap $4.70BP/E 27.6Yield –
Stevanato Group S.p.A. grew revenue 7.4% to €1.19B over fiscal 2025. Operating income rose 23.4% to €198.80M, moving the operating margin from 14.6% to 16.8%. Free cash flow was €22.32M. At the latest close the market valued the company at €4.26B, 27.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- €4.26B
- P/E ratio
- 27.6
- Price to sales
- 3.59
- Price to book
- 2.87
- Dividend yield
- –
- Free cash flow yield
- 0.52%
Fundamentals
- Revenue
- €1.19B
- Net income
- €139.84M
- EPS, diluted
- 0.51 EUR
- Free cash flow
- €22.32M
Trading
- Previous close
- $15.80
- Open
- $15.57
- Day's range
- $15.12 – $15.90
- Volume
- 1,083,259
- Average volume (20 days)
- 1,273,784
- RSI (14 days)
- 41.2
- Volatility (1 year)
- 55.1%
- Relative volume
- 1.93×
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | STVN | S&P 500 | Difference | STVN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.8% | -3.1% | −14.8 pts | ||
| 3 months | -26.3% | -4.5% | −21.8 pts | ||
| Year to date | -22.5% | +9.4% | −31.9 pts | ||
| 1 year | -29.4% | +11.3% | −40.7 pts | ||
| 3 years | -41.0% | +70.4% | −111.4 pts | -16.1% | +19.4% |
| 5 years | -28.5% | +68.6% | −97.1 pts | -6.5% | +11.0% |
Eight years at a glance
Fiscal years 2018 to 2025, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Stevanato Group S.p.A. filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Stevanato Group S.p.A.
Surgical & Medical Instruments & Apparatus
Stevanato Group S.p.A. provides drug containment, drug delivery, and diagnostic solutions, alongside manufacturing engineering systems for the pharmaceutical, biotechnology, and life sciences industries. It operates through two primary segments: Biopharmaceutical and Diagnostic Solutions, which supplies products such as pre-fillable syringes, vials, cartridges, diagnostic consumables, and drug delivery devices; and Engineering, which designs visual inspection, assembly, packaging, and serialization machinery. The company primarily serves global pharmaceutical, biotechnology, and diagnostic businesses, supporting their drug product life cycles from research through commercial production.
Company profile, executives and historyStevanato Group S.p.A. stock: common questions
What is Stevanato Group S.p.A.'s stock price?
STVN closed at $15.53 on Nov 16, 2026, down 1.71% on the day.
What is Stevanato Group S.p.A.'s market cap?
Stevanato Group S.p.A. was worth $4.70B at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is STVN's P/E ratio?
STVN trades at 27.6 times earnings, based on diluted earnings per share of 0.51 EUR over fiscal 2025.
How much revenue does Stevanato Group S.p.A. make?
Stevanato Group S.p.A. reported revenue of €1.19B for fiscal 2025, up 7.4% from a year earlier.
Does Stevanato Group S.p.A. pay a dividend?
No. Stevanato Group S.p.A. has not paid a cash dividend over the last twelve months.
How has STVN stock performed over the past year?
Including dividends, STVN returned -29.4% over the past year, against +11.3% for the S&P 500.
Who are Stevanato Group S.p.A.'s competitors?
Companies most similar to Stevanato Group S.p.A. by business, industry and size include WST, MMSI, IART, EMBC, TFX.
See a number that looks wrong?